76 related articles for article (PubMed ID: 21854086)
1. Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Cannella L; Loglisci G; Nanni M; De Cuia MR; Colafigli G; Salaroli A; Serrao A; Alimena G; Breccia M
Leuk Lymphoma; 2012 Mar; 53(3):497-8. PubMed ID: 21854086
[No Abstract] [Full Text] [Related]
2. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
[No Abstract] [Full Text] [Related]
3. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
[No Abstract] [Full Text] [Related]
4. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment.
Royer-Pokora B; Hildebrandt B; Redmann A; Herold C; Kronenwett R; Haas R; Drechsler M; Wieland C
Leukemia; 2003 Apr; 17(4):807-10. PubMed ID: 12682644
[No Abstract] [Full Text] [Related]
5. CML: the good, the better, and the difficult choices.
Cortes J
Blood; 2012 Nov; 120(19):3866-7. PubMed ID: 23144157
[No Abstract] [Full Text] [Related]
6. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
Feldman E; Najfeld V; Schuster M; Roboz G; Chadburn A; Silver RT
Exp Hematol; 2003 Aug; 31(8):702-7. PubMed ID: 12901975
[TBL] [Abstract][Full Text] [Related]
7. Even better kinase inhibitors for chronic myeloid leukemia.
Sawyers CL
N Engl J Med; 2010 Jun; 362(24):2314-5. PubMed ID: 20525994
[No Abstract] [Full Text] [Related]
8. Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
Roy L; Tomowiak C; Guilhot F
Blood; 2011 Nov; 118(19):5096-8. PubMed ID: 21876122
[No Abstract] [Full Text] [Related]
9. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
Fava C; Cortes J
Am J Hematol; 2008 Sep; 83(9):755. PubMed ID: 18615551
[No Abstract] [Full Text] [Related]
10. [The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment].
Zhang Y; Jiang Q; Qiu JY; Chen SS; Jiang B; Huang XJ
Zhonghua Nei Ke Za Zhi; 2007 Aug; 46(8):648-50. PubMed ID: 17967235
[TBL] [Abstract][Full Text] [Related]
11. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
Zaccaria A; Valenti AM; Donti E; Gozzetti A; Ronconi S; Spedicato F
Haematologica; 2007 Apr; 92(4):564-5. PubMed ID: 17488671
[TBL] [Abstract][Full Text] [Related]
12. Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Palandri F; Testoni N; Luatti S; Marzocchi G; Baldazzi C; Stacchini M; Castagnetti F; Breccia M; Specchia G; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G
Leuk Lymphoma; 2009 Jan; 50(1):114-8. PubMed ID: 19125382
[No Abstract] [Full Text] [Related]
13. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
[TBL] [Abstract][Full Text] [Related]
17. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
18. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
Luatti S; Castagnetti F; Marzocchi G; Baldazzi C; Gugliotta G; Iacobucci I; Specchia G; Zanatta L; Rege-Cambrin G; Mancini M; Abruzzese E; Zaccaria A; Grimoldi MG; Gozzetti A; Ameli G; Capucci MA; Palka G; Bernasconi P; Palandri F; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; Testoni N;
Blood; 2012 Jul; 120(4):761-7. PubMed ID: 22692507
[TBL] [Abstract][Full Text] [Related]
19. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
Ross DM; Jackson SR; Browett PJ
Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
[No Abstract] [Full Text] [Related]
20. Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
Breccia M; Latagliata R; Molica M; Colafigli G; Mancini M; Diverio D; Tafuri A; Alimena G
Am J Hematol; 2015 May; 90(5):E95-6. PubMed ID: 25683237
[No Abstract] [Full Text] [Related]
[Next] [New Search]
